Shattuck Labs, Inc. (STTK) Stock

Shattuck Labs, Inc. (STTK) is a Healthcare stock trading at $4.96 (as of 2026-06-18), with a market capitalization of $456.25M and a trailing P/E of -10.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Shattuck Labs, Inc. is a clinical-stage biotechnology company developing therapeutics for cancer and autoimmune disease. Its clinical-stage pipeline includes SL-172154 for ovarian, fallopian tube, and peritoneal cancers and SL-279252 for advanced solid tumors and lymphoma, with development based in the United States.

Valuation — source: SEC EDGAR (first-party)
Price	$4.96
Market Cap	$456.25M
P/E Ratio	-10.6
EV / EBITDA	-7.5
Price / Book	4.76
Price / Sales	456.25
DCF Value (model)	$-8.75
DCF Upside vs Price	-276.2%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$1.00M
Net Margin	-4880.9%
Return on Equity	-52.0%
Current Ratio	22.06
Revenue Growth (YoY)	-82.5%
EPS Growth (YoY)	-53.0%
FCF Growth (YoY)	-34.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	17.20 (safe)

Valuation vs Sector & Industry
Stock P/E	-10.6
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-150.9%
vs Industry	-162.5%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	PIPER SANDLER & CO. ($253.77M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Taylor H. Schreiber
Employees	44
Country	US
IPO Date	2020-10-09

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.